Galapagos Genomics
Encyclopedia
Galapagos Genomics NV was founded in 1999 as a joint venture between Crucell
(formerly IntroGene) and Tibotec
. The Company later changed its name to Galapagos NV
and completed its initial public offering on Euronext
Amsterdam and Euronext Brussels in May 2005.
The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins.
Onno van de Stolpe
is the CEO of the company.
Crucell
Crucell is a biotechnology company specializing in vaccines and antibodies. The firm, a subsidiary of Johnson & Johnson, is headquartered in Leiden, Netherlands...
(formerly IntroGene) and Tibotec
Tibotec
Tibotec is a pharmaceutical company with a focus on research and development for the treatment of infectious diseases such as HIV , and Hepatitis C...
. The Company later changed its name to Galapagos NV
Galapagos NV
Galapagos is a mid-size biotechnology company specialized in the discovery and development of small molecule and antibody therapies with novel modes-of-action. The Company is progressing one of the largest pipelines in biotech, with seven clinical and over 50 small molecule discovery/pre-clinical...
and completed its initial public offering on Euronext
Amsterdam and Euronext Brussels in May 2005.
The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins.
Onno van de Stolpe
Onno van de Stolpe
Onno van de Stolpe is a Dutch businessman and is currently the CEO of Galapagos, a drug discovery and development company.-Education:He obtained an MSc degree from the Agricultural University in Wageningen ....
is the CEO of the company.